Vincerx Pharma (NASDAQ:VINC) PT Lowered to $6.00 at SVB Leerink

Vincerx Pharma (NASDAQ:VINCGet Rating) had its target price cut by SVB Leerink from $19.00 to $6.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s price target would indicate a potential upside of 227.87% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright lifted their price target on shares of Vincerx Pharma from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, March 29th. Chardan Capital dropped their price target on shares of Vincerx Pharma from $30.00 to $14.00 in a research report on Wednesday, March 30th. Zacks Investment Research cut shares of Vincerx Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th. Finally, B. Riley dropped their price target on shares of Vincerx Pharma from $26.00 to $12.00 in a research report on Tuesday, April 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $16.89.

Vincerx Pharma stock opened at $1.83 on Tuesday. Vincerx Pharma has a 12-month low of $1.40 and a 12-month high of $18.43. The stock has a market cap of $38.54 million, a P/E ratio of -0.70 and a beta of 1.66. The company has a 50-day moving average price of $2.57 and a 200 day moving average price of $5.85.

Vincerx Pharma (NASDAQ:VINCGet Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.08. Research analysts anticipate that Vincerx Pharma will post -3.17 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in VINC. Deerfield Management Company L.P. Series C acquired a new position in shares of Vincerx Pharma in the 3rd quarter valued at $22,303,000. Rock Springs Capital Management LP acquired a new position in Vincerx Pharma in the 3rd quarter valued at $12,941,000. Sphera Funds Management LTD. increased its stake in Vincerx Pharma by 187.8% in the 3rd quarter. Sphera Funds Management LTD. now owns 654,572 shares of the company’s stock valued at $10,584,000 after buying an additional 427,122 shares during the period. BlackRock Inc. increased its stake in Vincerx Pharma by 123.2% in the 3rd quarter. BlackRock Inc. now owns 728,091 shares of the company’s stock valued at $11,773,000 after buying an additional 401,857 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in Vincerx Pharma in the 3rd quarter valued at $5,138,000. 78.01% of the stock is currently owned by institutional investors and hedge funds.

Vincerx Pharma Company Profile (Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Featured Stories

Stock Target Advisor logo

Analyst Recommendations for Vincerx Pharma (NASDAQ:VINC)

Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.